Patent ID: 11872226
Assignee: MEDIBIOFARMA, S.L.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 14:
15. A combination product comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and at least a therapeutic agent selected from the group consisting of chemotherapeutics agents, anti-inflammatory agents, steroids, immunosuppressants, immunotherapeutic agents, therapeutic antibodies and EP4 and/or EP2 modulators, in particular those selected from the group consisting of antibodies anti-CTLA4, selected from Ipilimumab and tremelimumab, antibodies anti-PD1 such as nivolumab, pembrolizumab, cemiplimab, pidilizumab, spartalizumab, MEDI0680, REGN2810 and AMP-224, antibodies anti-POL1 such as Atezolizumab, Avelumab, Durvalumab, and MDX-1105; Carboplatin, Carmustine (BCNU), Cisplatin, Cyclophosphamide, Etoposide, lrinotecan, Lomustine (CCNU), Methotrexate, Procarbazine, Temozolomide, Vincristine.